Key facts
- It has raised $5.4M; the latest was Later Stage VC in Jan 2026.
- Notable investors include IDG Capital, K2VC, CITIC Medical & Heath Group, Shenzhen Jiadaogu Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Supreme Life
- ·The full record, as it builds
Funding rounds
No funding rounds for Supreme Life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Supreme Life
Developer of traditional Chinese medicine designed to diagnose and treat common diseases. The company's medicine utilizes Chinese traditional medicine derived from ancient classic prescriptions to treat diseases, like diabetes, effectively replacing oral medicine and reducing insulin-injection amounts as well as other diseases, including hyperlipidemia, high blood pressure, sleep disorders, breast nodules, and early breast cancer, providing patients with an alternative treatment to mitigate and treat diseases.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2020
- Website
- supremelife.cn/
- Ownership
- Privately Held (backing)
Supreme Life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Supreme Life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Supreme Life in its N-PORT filings yet. We sweep new filings monthly.